FDA – Page 66 – Pharma.Tips

Data exclusivity lapse risk during lifecycle management – preventing repeat IP exposure

Mitigating Data Exclusivity Lapse Risks During Lifecycle Management As pharmaceutical companies maneuver through the complex landscape of lifecycle management, the risk of data exclusivity lapses can pose significant challenges. When…

Inventory control failure during distribution qualification – product quality risk assessment

Risk Assessment for Inventory Control Failures During Distribution Qualification Inventory control failures during the distribution qualification phase can lead to significant risks in product quality and regulatory compliance. Such situations…

Data exclusivity lapse risk during commercialization – risk mitigation and governance actions

Understanding and Mitigating Data Exclusivity Lapse Risks During Commercialization In today’s competitive pharmaceutical landscape, protecting your intellectual property through data exclusivity is crucial. However, lapses can occur during commercialization, leading…

Distribution temperature breach during storage – regulatory inspection outcome

Analyzing the Consequences of a Distribution Temperature Breach During Storage: An Investigative Approach In the pharmaceutical industry, maintaining stringent temperature controls during distribution is critical for product integrity and compliance.…

IP risks during tech transfer during lifecycle management – business and regulatory impact analysis

Understanding IP Risks During the Tech Transfer Process in Lifecycle Management In today’s pharmaceutical landscape, the transfer of technology during the product lifecycle presents notable risks, particularly regarding intellectual property…

Distribution temperature breach during inspection – regulatory inspection outcome

Analyzing a Distribution Temperature Breach During Inspection: Insights and Actions Experiencing a distribution temperature breach during an inspection can lead to serious regulatory repercussions and compromise product integrity. This article…

Freedom-to-operate gaps during due diligence – preventing repeat IP exposure

Identifying and Resolving Freedom-to-Operate Gaps During Due Diligence in Pharma The increasing complexity of pharmaceutical IP landscapes necessitates diligent oversight during due diligence processes. Low awareness or proactive measures can…

Transport qualification gaps during distribution qualification – how to prevent repeat excursions

Identifying and Addressing Transport Qualification Gaps During Distribution Qualification Transport qualification is a critical aspect of ensuring the integrity of pharmaceutical products during their distribution. Yet, lapses in this process…

IP risks during tech transfer during commercialization – preventing repeat IP exposure

Understanding and Mitigating IP Risks During Tech Transfer in Commercialization In the pharmaceutical sector, the transfer of technology during the commercialization phase is a critical but complex process that can…

Inventory control failure during audit – product quality risk assessment

Assessing Product Quality Risks from Inventory Control Failures during Audits Inventory control failures can pose significant risks to product quality and regulatory compliance in pharmaceutical operations. In this article, we…

Partner IP obligations missed during development – documentation expectations for audits

Understanding the Oversight of Partner IP Obligations During Development: A Structured Investigation In the complex landscape of pharmaceutical manufacturing, the inadvertent oversight of partner IP obligations can lead to significant…

Distribution temperature breach during distribution qualification – CAPA and system remediation

Addressing Distribution Temperature Breaches During Qualification: A Comprehensive Investigation Distribution temperature breaches can significantly jeopardize product integrity and compliance within pharmaceutical operations. A breach during distribution qualification can lead to…